◆ NeutralCORGMEDVCYTWST
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Zacks Investment Research·
Cencora's U.S. Healthcare Solutions business demonstrated accelerating momentum with 5% revenue growth and 16% operating income growth in Q3, driven by specialty strength and OneOncology's performance. However, the company faces headwinds from manufacturer list-price reductions, the pending MWI divestiture expected to create a $150 million earnings impact, and regulatory uncertainty around 340B and ASP rules. GLP-1 growth and international operations provide diversification opportunities.
Read Full Article at Zacks Investment Research →